Characterization of α4β1 (CD49d/CD29) on equine leukocytes: Potential utility of a potent α4β1 (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction)

Veterinary Immunology and Immunopathology

Volumn 130, Issue 1-2, 2009, Pages 79-87

  Treonze, Kelly M ^a   Alves, Kenneth ^a   Fischer, Paul ^a   Hagmann, William K ^a   Hora, Donald ^a   Kulick, Alison ^a   Vakerich, Ken ^a   Smith, Nicholas D ^a   Lingham, Russell B ^a   Maniar, Salony ^a   Reger, Thomas S ^a   Zunic, Jasmine ^a   Munoz, Benito ^a   Prasit, Peppi ^a   Nicholson, Donald ^a   Si, Qian ^a   Judd, Keith ^a   Nicolich, Susan ^a   Kellerhouse, Patricia ^a   Thompson, Donald ^a   Mumford, Richard A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

4 1; CD49d CD29; Heaves; Horse; Recurrent airway obstruction; VLA 4

Indexed keywords

IMMUNOMODULATING AGENT; RESPIRATORY TRACT AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 4 RECEPTOR ANTAGONIST;

AIRWAY OBSTRUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BOLUS INJECTION; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG INFUSION; DRUG POTENCY; DRUG STRUCTURE; FEMALE; HORSE DISEASE; HUMAN; IC 50; LEUKOCYTE ACTIVATION; LEUKOCYTOSIS; MALE; MOLECULAR WEIGHT; MORNING DOSAGE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SINGLE DRUG DOSE;

AIRWAY OBSTRUCTION; ANIMALS; BINDING, COMPETITIVE; DOGS; FEMALE; FLOW CYTOMETRY; HORSE DISEASES; HORSES; INTEGRIN ALPHA4BETA1; LEUKOCYTES; MACACA MULATTA; MALE; RATS; RATS, SPRAGUE-DAWLEY;

CANIS FAMILIARIS; EQUIDAE; MACACA MULATTA;

EID: 67349095055     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.01.011     Document Type: Article

References (22)

1. Butcher E.C. Mucosal Immunity. 2nd ed. (1999), Academic Press, San Diego pp. 507-522
2. Chen L.L., Whitty A., Lobb R.R., Adams S.P., and Pepinsky R.B. Multiple activation states of integrin alpha4beta1 detected through their different affinities for a small molecule ligand. J. Biol. Chem. 274 (1999) 13167-13175
3. Dewachi O., Jouibert P., Hamid Q., and Lavoie J.P. Expression of interleukin (IL)-5 and IL-9 receptors on neutrophils of horses with heaves. Vet. Immun. Immunopathol. 109 (2006) 31-36
4. Doherty G.A., Yang G.X., Borges E., Tong S., McCauley E.D., Treonz K.M., Van Riper G., Pacholok S., Si Q., Koo G.C., Shah K., Mumford R.A., and Hagmann W.K. N-isonicotinoyl-(l)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists. Bioorg. Med. Chem. Lett. 13 (2003) 1891-1895
5. Doherty, G., Lin, L.S., Hagmann, W.K., Yang, G.X.-Q., Chang, L.L., Shah, S.K., Mumford, R.A., Kamenecka, T., 2005. Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors. US Pat. 6,943,180 B2.
6. Fairbairn S.M., Page C.P., Lees P., and Cunningham F.M. Early neutrophil but not eosinophil or platelet recruitment to the lungs of allergic horses following antigen exposure. Clin. Exp. Allergy 23 (1993) 821-828
7. Hagmann, W.K., Lin, L.S., Liu, P., Mumford, R.A., Reger, T.S., Smith, N.D., Stock, N.S., Zunic, J., 2005. VLA-4 Antagonists. PCT Pat. Applic. WO2005087760A1.
8. Hemler M.E., Elices M.J., Parker C., and Takada Y. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol. Rev. 114 (1990) 45-65
9. Hijazi Y., Welker H., Dorr A.E., Tang J.P., Blain R., Renzetti L.M., and Abbas R. Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J. Clin. Pharmacol. 44 (2004) 1368-1378
10. Ibbotson G.C., Doig C., Kaur J., Gill V., Ostrovsky L., Fairhead T., and Kubes P. Functional alpha4-integrin: a newly identified pathway of neutrophil recruitment in critically ill septic patients. Nat. Med. 7 (2001) 465-470
11. Koo G.C., Shah K., Ding G.J., Xiao J., Wnek R., Doherty G., Tong X.C., Pepinsky R.B., Lin K.C., Hagmann W.K., Kawka D., and Singer I.I. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am. J. Respir. Crit. Care Med. 167 (2003) 1400-1409
12. Leone D.R., Giza K., Gill A., Dolinski B.M., Yang W., Perper S., Scott D.M., Lee W.C., Cornebise M., Wortham K., Nickerson-Nutter C., Chen L.L., LePage D., Spell J.C., Whalley E.T., Petter R.C., Adams S.P., Lobb R.R., and Pepinsky R.B. An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 305 (2003) 1150-1162
13. Lobb R.R., and Hemler M.E. The pathophysiologic role of alpha 4 integrins in vivo. J. Clin. Invest. 94 (1994) 1722-1728
14. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W., and International Natalizumab Multiple Sclerosis Trial Group. Controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003) 15-23
15. Pepinsky R.B., Mumford R.A., Chen L.L., Leone D., Amo S.E., Van Riper G., Whitty A., Dolinski B., Lobb R.R., Dean D.C., Chang L.L., Raab C.E., Si Q., Hagmann W.K., and Lingham R.B. Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1. Biochemistry 41 (2002) 7125-7141
16. Robinson N.E., Derksen F.J., Olszewski M.A., and Buechner-Maxwell V.A. The pathogenesis of chronic obstructive pulmonary disease of horses. Br. Vet. J. 152 (1996) 283-306
17. Robinson N.E. Proceedings of the International Workshop on Equine Chronic Airway Disease. Michigan State University, 16-18 June. Equine Vet. J. 33 (2000) 5-19
18. Robinson N.E., Jackson C., Jefcoat A., Berney C., Peroni D., and Derksen F.J. Efficacy of three corticosteroids for the treatment of heaves. Equine Vet. J. 34 (2002) 17-22
19. Rush B.R., Flaminio J.B.F., Matson C.J., Hakala J.E., and Shuman W. Cytological evaluation of bronchoalveolar lavage fluid from horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone respectively. Am. J. Vet. Res. 59 (1998) 1033-1038
20. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., Panaccione R., Sanders M., Schreiber S., Targan S., van Deventer S., Goldblum R., Despain D., Hogge G.S., and Rutgeerts P.N. The International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group and The Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group, 2005. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353 (2005) 1912-1925
21. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 (1994) 301-314
22. Taooka Y., Chen J., Yednock T., and Sheppard D. The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. J. Cell Biol. 145 (1999) 413-420